In the second part of Parallax’s review of 2021, Dr Sukh Nijjer, Interventional Cardiologist from Imperial College London, and Dr Ankur Kalra discuss key advances in the field of heart failure and cardiac surgery.
SGLT2 inhibitors are proving to be the blockbuster drug of this decade: Sukh summarises and compares the learnings from DAPA-HF, Emperor-Reduced, and Emperor-Preserved. Next, Sukh highlights the data from SOLOIST-WHF that showed sotagliflozin to have beneficial effects on CV outcomes among patients with type 2 diabetes and HF. Additionally, they discuss how findings on finerenone (FIGARO-DKD) will shape the field. Sukh talks about the semaglutide and the STEP studies, an injectable medication that further expends cardiologist knowledge beyond their speciality. Ankur and Sukh reflect on how the advancement of this field shaped their own practices.
2021 was a busy year for cardiac surgery trials: Sukh and Ankur review the most pertinent data from the AVATAR randomised study presented at AHA 2021. Sukh interprets the outcomes and asks Ankur about his clinical experiences. Finally, they review the investigator led LAAOS III study that showed patients with atrial fibrillation undergoing cardiac surgery, left atrial appendage occlusion was superior to no occlusion.
What were the top practice informing heart failure trials of 2021? What does the latest data say on current cardiac surgery practices? How will these findings inform patient care?
Questions and comments can be sent to “podcast@radciffe-group.com” and may be answered by Ankur in the next episode. Guest @SukhNijjer, hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Brought to you by Edwards: www.edwardstavr.com
Tune in to discover the strategies that Dr. Kalra and Dr. Alasnag are currently employing and gain insights into how these data will shape their future decision-making in the catheterization laboratory. Don't miss this informative discussion at the forefront of interventional cardiology.
As we adapt to the changes brought about by the pandemic, Dr Singh outlines the necessary steps to foster a reality in which we can utilize these technologies to create more time for human connection.
Dr Owens is Medical Director of the Center for Inherited Cardiac Disease and Associate Professor of Medicine at the Hospital of the University of Pennsylvania.
This series is supported by an unrestricted educational grant from Bristol Myers Squibb. Please see www.camzyosrems.com for important safety information.
This content is intended for US-based physicians.
This series is supported by an unrestricted educational grant from Bristol Myers Squibb. Please see www.camzyosrems.com for important safety information.
This content is intended for US-based physicians.
This series is supported by an unrestricted educational grant from Bristol Myers Squibb. Please see www.camzyosrems.com for important safety information.
This content is intended for US-based physicians.
In this rich and insightful discussion, Dr Kittleson talks about the origins of famous #kittlesonrules, a collection of tips for doctors shared on Twitter, and her thoughts on mentorship. We learn more about Mastering the Art of Patient Care. Dr Kalra and Dr Kittleson discuss strategies for managing difficult situations in patient care.
What do you need to know about hospital investigations? What is the difference between OPPE and FPPE? How can you get educated on hospital bylaws and processes?
Rohin shares an advice that he received at the beginning of his career: “If you can deal with an average day, the exciting day will take care of itself.”
Ankur asks Rohin about Medlife Crisis and the work that goes into producing a show followed by 500K people. Rohin reiterates his passion for research and science communication. Ankur and Rohin discuss what it means to be yourself on social media and what is Rohin’s advice to our early-career listeners.
In this information-packed episode, Dr Patel takes us behind the scenes and talks about the work that goes into the curation of the programme and the considerations that shape the event. Dr Kalra asks Dr Patel about his highlights over the years and the movement and changes that he observed as vice chair and chair of the event. Dr Patel elaborates on the key late-breaking science trials in 2022. Dr Kalra and Dr Patel discuss the grading system of the award applications and share some useful information with our listeners.